Viridian Therapeutics: A Look at Second Quarter 2022 Financial Results and Exciting Corporate Updates
Viridian Therapeutics: A Look at Second Quarter 2022 Financial Results and Exciting Corporate Updates Positive Developments in Clinical Trials In the second quarter of 2022, Viridian Therapeutics, a cutting-edge biotechnology company, reported promising results from their ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED). The initial clinical data showed positive…